Locations:
Search IconSearch
March 23, 2017/Cancer/News & Insight

New Cancer Center Houses Ohio’s Most Advanced Gamma Knife Technology

Icon one of many upgrades in new building

suh-icon_650x450

The new Taussig Cancer Center building, which opened March 6, 2017, houses Ohio’s first Leksell Gamma Knife Icon™ radiosurgery technology. Icon offers the most precise brain radiosurgery capabilities of any currently available technology.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The addition of this new technology further enhances patient care, research and education at Cleveland Clinic Cancer Center. Since 1997, the center has performed over 6000 cases using Gamma Knife for brain tumor treatment. Cleveland Clinic is also one of the few centers to offer a week-long Gamma Knife training course, which has trained hundreds of physicians and medical physicists. In addition, the center is active in scientific and clinical research, has ongoing clinical trials for patients with brain metastases and holds an annual international symposium on radiosurgery.

Upgraded features benefit patient care

Icon’s front-mounted, cone-beam CT scanner allows the physician to verify the patient’s head position prior to treatment. This verification enables physicians to treat tumors in locations close to critical structures such as the optic apparatus and brain stem, and to replace rigid frames that screw into a patient’s skull with a mask as a stereotactic reference.

The mask “offers a better patient experience for some patients and allows us to divide treatments over multiple sessions, which is useful for some complex cases,” says John Suh, MD, Chair of the Department of Radiation Oncology at Cleveland Clinic’s Taussig Cancer Center and Associate Director of the Gamma Knife Center. The presence of high-definition motion management, which uses an infrared camera, monitors any patient motion during treatment.

Icon one of many upgrades in new building

The new 377,000-square-foot, $276 million Cancer Center building is designed, top to bottom, to “optimize multidisciplinary care and patient experience and minimize wait times,” says Dr. Suh. The light-filled building extends its brightness to the lower level of the radiation treatment center with an enormous standing skylight that protrudes into the parking drop off area. “The presence of natural light into the radiation oncology department is very important. It helps make the space more open and inviting, which helps comfort patients and their families,” says Dr. Suh.

Advertisement

All radiation treatments will occur in the new Cancer Center. Six state-of-the-art linear accelerators with image guidance, two large bore CT simulators, a hyperthermia suite, a high-dose rate brachytherapy suite and MRI for simulation will join Icon in the array of radiation treatments available for Cleveland Clinic patients. In addition, the lower level will feature a large physician conference room with two 100-inch monitors.

“It’s a very exciting time in oncology, in particular radiation oncology,” says Dr. Suh. “We plan to create the future of cancer care in the new Taussig Cancer Center by providing timely, compassionate, innovative and comprehensive cancer care.”

Advertisement

Related Articles

Patient holding loved one's hand
November 7, 2025/Cancer/News & Insight
Facing Fear: How to Help Patients Navigate Cancer Anxiety

Psychosocial oncology offers a path forward

Dr. Jame Abraham
October 20, 2025/Cancer/News & Insight
Trastuzumab Deruxtecan Improves Invasive Disease-Free Survival of Early-Stage HER+ Breast Cancer by 53%

International study supports change in clinical care in post-neoadjuvant setting

Dr. Khouri and patient
October 15, 2025/Cancer/News & Insight
BCL-2 Inhibition in Plasma Cell Disorders: The Work Continues

Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma

Dr. Mustafa Ali and patient
September 30, 2025/Cancer/News & Insight
Cytogenetic Response to Treatment Correlates With Long-Term Survival of Patients With Acute Myeloid Leukemia

New system refines classification of cytogenetic abnormalities at time of response assessment and their clinical significance

Social worker with patient
September 9, 2025/Cancer/News & Insight
Oncology Social Work a Lifeline in Blood Cancer Treatment

Lifetime Achievement award-winner reflects on psychosocial support and caregiver readiness

Dr. Mustafa Ali & patient
September 4, 2025/Cancer/News & Insight
Comparison of First-Line Chemotherapy for Adults with Acute Lymphoblastic Leukemia

Questions remain about the merits of asparaginase-based therapy

monoclonal antibody illustration
August 22, 2025/Cancer/News & Insight
New Essential Thrombocythemia Treatment Appears to Address Underlying Disease

Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities

Ad